According to research report the clinical microbiology market
is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in
2018 growing at a CAGR of 6.4% during forecast period. The technological
advancements in disease diagnostics, rising incidence of infectious
diseases (such as tuberculosis, malaria, respiratory infections, and
STDs) coupled with growing outbreak of epidemics (such as swine flu,
zika virus, and yellow fever), and increased funding and public-private
investments for development of disease diagnosis technology are key
factors driving the growth of this market
Read More: https://www.marketsandmarkets.com/PressReleases/microbiology-testing.asp
The pharmaceutical applications are expected to dominate the global microbiology testing market in 2018
The microbiology testing market is segmented on the basis of applications into pharmaceutical, clinical, food testing, energy, chemical and material manufacturing, and environmental applications. The pharmaceutical applications segment is expected to dominate the overall microbial testing market in 2018 due to the presence of well-established and globally accepted regulations that govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing processes.
The laboratory instruments are projected to hold the largest share of the clinical microbiology instruments market in 2018
The clinical microbiology market is segmented on the basis of products into instruments (laboratory instruments and microbiology analyzers) and reagents (pathogen-specific kits and general reagents). The laboratory instruments products segment is expected to command the largest share of the global clinical microbiology instruments market in 2018 due to factors such as continuous technological advancements in the field of microbiology testing instruments and the focus on laboratory automation (coupled with the integration of robotics with conventional microbiology instruments).
The respiratory diseases are expected to be the largest diseases area in clinical microbiology market in 2018
On the basis of disease area, the clinical microbiology market is segmented into respiratory diseases, bloodstream infections (BSIs), gastrointestinal (GI) diseases, sexually transmitted diseases (STDs), urinary tract infections (UTIs), periodontal diseases, and other diseases (including cardiovascular disease, central nervous system infections, connective tissue & joint diseases, and skin diseases). The respiratory disease segment is estimated to account for largest share of the global clinical microbiology market owing to the large patient population suffering from respiratory diseases, rising prevalence of target respiratory diseases (including TB, asthma, COPD, and bronchitis) across developing countries, and increasing number of epidemic outbreaks of respiratory infections.
North America is expected to dominate the clinical microbiology market in 2018
Geographically, the market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of APAC), and the Rest of the World (Latin America, and the Middle East and Africa). North America is expected to account for the largest share of the global clinical microbiology market in 2018 due to easy accessibility and high adoption of advanced diagnostic techniques, technological advancements in microbial testing techniques, rising geriatric population, and growing public-private funding to support microbiology-based research in the region.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367
The major players operating in the microbiology testing/clinical microbiology market are bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.
Read More: https://www.marketsandmarkets.com/PressReleases/microbiology-testing.asp
The pharmaceutical applications are expected to dominate the global microbiology testing market in 2018
The microbiology testing market is segmented on the basis of applications into pharmaceutical, clinical, food testing, energy, chemical and material manufacturing, and environmental applications. The pharmaceutical applications segment is expected to dominate the overall microbial testing market in 2018 due to the presence of well-established and globally accepted regulations that govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing processes.
The laboratory instruments are projected to hold the largest share of the clinical microbiology instruments market in 2018
The clinical microbiology market is segmented on the basis of products into instruments (laboratory instruments and microbiology analyzers) and reagents (pathogen-specific kits and general reagents). The laboratory instruments products segment is expected to command the largest share of the global clinical microbiology instruments market in 2018 due to factors such as continuous technological advancements in the field of microbiology testing instruments and the focus on laboratory automation (coupled with the integration of robotics with conventional microbiology instruments).
The respiratory diseases are expected to be the largest diseases area in clinical microbiology market in 2018
On the basis of disease area, the clinical microbiology market is segmented into respiratory diseases, bloodstream infections (BSIs), gastrointestinal (GI) diseases, sexually transmitted diseases (STDs), urinary tract infections (UTIs), periodontal diseases, and other diseases (including cardiovascular disease, central nervous system infections, connective tissue & joint diseases, and skin diseases). The respiratory disease segment is estimated to account for largest share of the global clinical microbiology market owing to the large patient population suffering from respiratory diseases, rising prevalence of target respiratory diseases (including TB, asthma, COPD, and bronchitis) across developing countries, and increasing number of epidemic outbreaks of respiratory infections.
North America is expected to dominate the clinical microbiology market in 2018
Geographically, the market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of APAC), and the Rest of the World (Latin America, and the Middle East and Africa). North America is expected to account for the largest share of the global clinical microbiology market in 2018 due to easy accessibility and high adoption of advanced diagnostic techniques, technological advancements in microbial testing techniques, rising geriatric population, and growing public-private funding to support microbiology-based research in the region.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367
The major players operating in the microbiology testing/clinical microbiology market are bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bruker Corporation (US), Hologic, Inc. (US), QIAGEN N.V. (The Netherlands), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Shimadzu Corporation (Japan), 3M Company (US), and Neogen Corporation (US), among others.
No comments:
Post a Comment